AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

682

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage IB-IIIA Non-small Cell Lung Carcinoma

Interventions

DRUG: AZD9291 80 mg/40 mg
DRUG: Placebo AZD9291 80 mg/40 mg
DRUG: Open-label AZD9291 80 mg/40 mg

Sponsor

AstraZeneca